

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC,
Petitioner

v.

ALKERMES PHARMA IRELAND LIMITED,
Patent Owner

Case IPR2018-00943
Patent 7,919,499

**DECLARATION OF
CORY J. BERKLAND, Ph.D.**

Contents

| | |
|---|----|
| INTRODUCTION | 3 |
| MY QUALIFICATIONS | 3 |
| LEGAL STANDARDS | 5 |
| OPINIONS | 8 |
| Claim Construction | 12 |
| (A) “the serum AUC of naltrexone . . . achieved by 50 mg/day oral administration” | 12 |
| (B) “the step of parenterally administering a long acting formulation comprising about 310 mg to about 480 mg of naltrexone” | 14 |
| (C) “initial oral dose of naltrexone” | 18 |
| Comer Does Not Anticipate the Claims (Amneal’s Ground 1) | 20 |
| (A) Comer Does Not Disclose “the step of parenterally administering a long acting formulation comprising about 310 mg to about 480 mg of naltrexone” | 22 |
| (B) Comer Does Not Disclose the Claimed AUC Differential | 22 |
| (C) Comer Does Not Disclose Treating | 27 |
| (D) At a Minimum, Certain Dependent Claims Are Not Anticipated | 27 |
| Nuwayser Does Not Anticipate the Claims (Amneal’s Ground 2) | 29 |
| (A) Nuwayser Does Not Disclose “the step of parenterally administering a long acting formulation comprising about 310 mg to about 480 mg of naltrexone” | 29 |
| (B) Nuwayser Does Not Disclose the Claimed AUC Differential | 30 |
| (C) Nuwayser Does Not Disclose the Claimed Dose | 30 |
| (D) At Minimum, Claim 11 is Not Anticipated | 31 |
| The Asserted Combinations Do Not Render the Claims Obvious | 31 |
| Comer, Nuwayser, Rubio, and Wright Do Not Render the Claims Obvious (Amneal’s Grounds 3 & 4) | 32 |

| | |
|---|----|
| (A) The Asserted Combination Does Not Disclose Key Claim Limitations | 32 |
| (B) A POSA Would Not Have Been Motivated or Had a Reasonable Expectation of Success in Combining the Asserted References..... | 33 |
| (C) At a Minimum, Certain Dependent Claims Are Not Obvious | 34 |
| Nuwayser, Kranzler, Rubio, and Wright Do Not Render the Claims Obvious (Amneal’s Ground 5)..... | 37 |
| (A) The Asserted Combination Does Not Disclose Key Claim Limitations | 37 |
| (B) A POSA Would Not Have Been Motivated or Had a Reasonable Expectation of Success in Combining the Asserted References..... | 38 |
| (C) At a Minimum, Certain Dependent Claims Are Not Obvious | 40 |
| Alkermes 10-K, Vivitrex Specimen, Rubio, and Wright Do Not Render the Claims Obvious (Amneal’s Ground 6)..... | 40 |

I, Cory J. Berkland, Ph.D., declare:

INTRODUCTION

1. I am of legal age and am competent to make this Declaration.
2. I understand that the Patent Trial and Appeal Board has granted Amneal Pharmaceuticals LLC's ("Amneal") Petition for *Inter Partes* Review of claims 1-13 of U.S. Patent No. 7,919,499 ("the '499 patent").

MY QUALIFICATIONS

3. My qualifications, professional experience, education, and publications are set forth in my curriculum vitae, attached as Appendix A. I provide a brief summary below.
4. I completed my undergraduate training in Chemical Engineering from Iowa State University, Ames, IA in 1998. I completed my post-graduate training from the University of Illinois, Urbana, IL and received my M.S. (in Chemical Engineering) and my Ph.D. (in Chemical and Biomolecular Engineering) in 2001 and 2003, respectively.
5. I am currently the Solon E. Summerfield Distinguished Professor at The University of Kansas. I am appointed as a Distinguished Professor in the Department of Pharmaceutical Chemistry in the School of Pharmacy and in the Department of Chemical & Petroleum Engineering in the School of Engineering. Since 2009, I have been a tenured professor in both the Department of

Pharmaceutical Chemistry and the Department of Chemical & Petroleum Engineering at The University of Kansas.

6. I have received numerous awards for my work in the field of nanoparticles and drug delivery, including recently being inducted into the American Institute for Medical and Biological Engineering (AIMBE) based, in part, for my work in controlled release drug delivery systems. I was also elected to the National Academy of Inventors as a result of my work in the pharmaceutical sciences.

7. I have been a thesis advisor and postgraduate-scholar sponsor for numerous students in the fields of Pharmaceutical Chemistry, Bioengineering, Chemistry, and Chemical Engineering.

8. I have taught a variety of classes on both the undergraduate and graduate level including classes titled, Emerging Trends in Pharmaceutical Chemistry, Drug Delivery, and Biopharmaceutics and Drug Delivery.

9. I have received recognition for my teaching including being awarded the W.T. Kemper Fellowship for Teaching Excellence (2010) and a Teaching Achievement Award (2007).

10. I am currently on, or have served on, multiple advisory boards for journals, including the Journal of Pharmaceutical Sciences, the Journal of Pharmaceutical Innovation, and the Journal of Therapeutic Delivery.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.